JP7258871B2 - 遺伝子及びゲノムの検査並びに分析におけるバリアント解釈の、監査可能な継続的な最適化のための分子エビデンスプラットフォーム - Google Patents

遺伝子及びゲノムの検査並びに分析におけるバリアント解釈の、監査可能な継続的な最適化のための分子エビデンスプラットフォーム Download PDF

Info

Publication number
JP7258871B2
JP7258871B2 JP2020522707A JP2020522707A JP7258871B2 JP 7258871 B2 JP7258871 B2 JP 7258871B2 JP 2020522707 A JP2020522707 A JP 2020522707A JP 2020522707 A JP2020522707 A JP 2020522707A JP 7258871 B2 JP7258871 B2 JP 7258871B2
Authority
JP
Japan
Prior art keywords
data
evidence
variant
performance
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020522707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537795A (ja
JP2020537795A5 (enExample
Inventor
アレクサンドル コラヴィン，
カルロス エル． アラヤ，
ジェイソン エー． ロイター，
Original Assignee
インビタエ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インビタエ コーポレイション filed Critical インビタエ コーポレイション
Publication of JP2020537795A publication Critical patent/JP2020537795A/ja
Publication of JP2020537795A5 publication Critical patent/JP2020537795A5/ja
Application granted granted Critical
Publication of JP7258871B2 publication Critical patent/JP7258871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
    • G06F18/211—Selection of the most significant subset of features
    • G06F18/2113—Selection of the most significant subset of features by ranking or filtering the set of features, e.g. using a measure of variance or of feature cross-correlation
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F18/00—Pattern recognition
    • G06F18/20—Analysing
    • G06F18/21—Design or setup of recognition systems or techniques; Extraction of features in feature space; Blind source separation
    • G06F18/217—Validation; Performance evaluation; Active pattern learning techniques
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N20/00—Machine learning
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/10—Ontologies; Annotations
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L67/00—Network arrangements or protocols for supporting network services or applications
    • H04L67/01—Protocols
    • H04L67/10—Protocols in which an application is distributed across nodes in the network
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
    • H04L9/06—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for block-wise or stream coding, e.g. DES systems or RC4; Hash functions; Pseudorandom sequence generators
    • H04L9/0618—Block ciphers, i.e. encrypting groups of characters of a plain text message using fixed encryption transformation
    • H04L9/0637—Modes of operation, e.g. cipher block chaining [CBC], electronic codebook [ECB] or Galois/counter mode [GCM]
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
    • H04L9/06—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for block-wise or stream coding, e.g. DES systems or RC4; Hash functions; Pseudorandom sequence generators
    • H04L9/0643—Hash functions, e.g. MD5, SHA, HMAC or f9 MAC
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L9/00—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols
    • H04L9/50—Cryptographic mechanisms or cryptographic arrangements for secret or secure communications; Network security protocols using hash chains, e.g. blockchains or hash trees

Landscapes

  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Databases & Information Systems (AREA)
  • Analytical Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioethics (AREA)
  • Molecular Biology (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Computation (AREA)
  • Genetics & Genomics (AREA)
  • Software Systems (AREA)
  • Computer Security & Cryptography (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Power Engineering (AREA)
  • Computing Systems (AREA)
  • Mathematical Physics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
JP2020522707A 2017-10-17 2018-10-17 遺伝子及びゲノムの検査並びに分析におけるバリアント解釈の、監査可能な継続的な最適化のための分子エビデンスプラットフォーム Active JP7258871B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762573458P 2017-10-17 2017-10-17
US62/573,458 2017-10-17
PCT/US2018/056304 WO2019079464A1 (en) 2017-10-17 2018-10-17 PLATFORM OF MOLECULAR EVIDENCE FOR CONTINUOUS AND VERIFY OPTIMIZATION OF INTERPRETATION OF VARIANTS IN TESTS AND GENETIC ANALYZES

Publications (3)

Publication Number Publication Date
JP2020537795A JP2020537795A (ja) 2020-12-24
JP2020537795A5 JP2020537795A5 (enExample) 2021-07-26
JP7258871B2 true JP7258871B2 (ja) 2023-04-17

Family

ID=66174641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020522707A Active JP7258871B2 (ja) 2017-10-17 2018-10-17 遺伝子及びゲノムの検査並びに分析におけるバリアント解釈の、監査可能な継続的な最適化のための分子エビデンスプラットフォーム

Country Status (10)

Country Link
US (4) US11462299B2 (enExample)
EP (1) EP3701534B1 (enExample)
JP (1) JP7258871B2 (enExample)
CN (1) CN112074909B (enExample)
AU (1) AU2018350975B2 (enExample)
BR (1) BR112020007449A2 (enExample)
CA (1) CA3079389A1 (enExample)
IL (1) IL274001A (enExample)
MX (1) MX2020003709A (enExample)
WO (1) WO2019079464A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3701534B1 (en) 2017-10-17 2024-04-10 Invitae Corporation Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis
US10959277B2 (en) * 2019-04-01 2021-03-23 T-Mobile Usa, Inc. Mobile device network performance restoration and improvement
US10764062B2 (en) * 2019-06-03 2020-09-01 Alibaba Group Holding Limited Blockchain ledger compression
CN110602162B (zh) * 2019-08-06 2022-11-01 苏州龙信信息科技有限公司 终端取证方法、装置、设备和存储介质
CN110957006B (zh) * 2019-12-14 2023-08-11 杭州联川基因诊断技术有限公司 一种brca1/2基因变异的解读方法
CN112489812B (zh) * 2020-11-30 2021-07-06 北京华彬立成科技有限公司 药物开发分析方法、装置、电子设备和存储介质
US20230351337A1 (en) * 2022-04-29 2023-11-02 Bank Of America Corporation Generating and securing digital checks using distributed ledger and embedded chip methods
US12211039B2 (en) * 2022-09-20 2025-01-28 Veiovia Limited Externally validated proof of work for appending a block record to a blockchain with a data broker server
US11652650B1 (en) * 2022-09-20 2023-05-16 Veiovia Limited Externally validated proof of work for appending a block record to a blockchain with a commitment database server
US12216661B2 (en) 2022-09-20 2025-02-04 Veiovia Ltd. Externally validated proof of work for appending a block record to a blockchain with a mining node
WO2025115360A1 (ja) * 2023-11-30 2025-06-05 富士フイルム株式会社 木構造生成方法、情報処理装置、情報処理システム、及び木構造生成プログラム
CN119719955B (zh) * 2024-12-17 2025-09-05 四川大学华西医院 一种基于贝叶斯模型的证据优化方法、装置、计算机设备及存储介质

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500647A (ja) 1995-10-24 2000-01-25 クレイジェン コーポレーション 配列決定を行なわないでサンプル中のｄｎａ配列を同定、分類または定量する方法及び装置
WO2016154584A1 (en) 2015-03-26 2016-09-29 Quest Diagnostics Investments Incorporated Alignment and variant sequencing analysis pipeline
US20160306923A1 (en) 2013-01-17 2016-10-20 Edico Genome, Inc. Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
US20170270212A1 (en) 2016-03-21 2017-09-21 Human Longevity, Inc. Genomic, metabolomic, and microbiomic search engine

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780236A (en) 1996-11-18 1998-07-14 Wisconsin Alumni Research Foundation Method for identifying mutants and molecules
US6949692B2 (en) 1996-11-18 2005-09-27 Wisconsin Alumni Research Foundation Method for identifying mutants and molecules
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US20060223058A1 (en) * 2005-04-01 2006-10-05 Perlegen Sciences, Inc. In vitro association studies
US7702468B2 (en) 2006-05-03 2010-04-20 Population Diagnostics, Inc. Evaluating genetic disorders
WO2008033239A2 (en) 2006-09-11 2008-03-20 Applera Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
KR101325736B1 (ko) * 2010-10-27 2013-11-08 삼성에스디에스 주식회사 바이오 마커 추출 장치 및 방법
US20130338012A1 (en) 2010-11-18 2013-12-19 Illumina Inc. Genetic risk factors of sick sinus syndrome
WO2012155148A2 (en) 2011-05-12 2012-11-15 University Of Utah Research Foundation Predicting gene variant pathogenicity
US8718950B2 (en) * 2011-07-08 2014-05-06 The Medical College Of Wisconsin, Inc. Methods and apparatus for identification of disease associated mutations
US9773091B2 (en) * 2011-10-31 2017-09-26 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
US9235686B2 (en) 2012-01-06 2016-01-12 Molecular Health Gmbh Systems and methods for using adverse event data to predict potential side effects
US20140089009A1 (en) * 2012-09-27 2014-03-27 Wobblebase, Inc. Method for Personal Genome Data Management
SG11201505969XA (en) * 2013-01-31 2015-08-28 Codexis Inc Methods, systems, and software for identifying bio-molecules with interacting components
US20160048633A1 (en) * 2013-03-15 2016-02-18 Cypher Genomics, Inc. Systems and methods for genomic variant annotation
WO2014151764A2 (en) * 2013-03-15 2014-09-25 Veracyte, Inc. Methods and compositions for classification of samples
US10235496B2 (en) * 2013-03-15 2019-03-19 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
JP6566484B2 (ja) * 2013-06-14 2019-08-28 キージーン ナムローゼ フェンノートシャップ 表現形質改善のための制御された戦略
US20150025861A1 (en) * 2013-07-17 2015-01-22 The Johns Hopkins University Genetic screening computing systems and methods
WO2015027085A1 (en) * 2013-08-22 2015-02-26 Genomoncology, Llc Computer-based systems and methods for analyzing genomes based on discrete data structures corresponding to genetic variants therein
US20160314245A1 (en) 2014-06-17 2016-10-27 Genepeeks, Inc. Device, system and method for assessing risk of variant-specific gene dysfunction
CN106796620A (zh) * 2014-06-30 2017-05-31 凯杰雷德伍德城公司 用于解释和报告基于序列的基因测试的方法和系统
EP3189619B1 (en) * 2014-09-03 2021-02-17 NantOmics, LLC Device, method and computer program product for synthetic genomic variant-based secure transaction
EP3286677A4 (en) * 2015-04-22 2019-07-24 Genepeeks, Inc. DEVICE, SYSTEM AND METHOD FOR ASSESSING THE RISK OF VARIATION SPECIFIC GENDYS FUNCTION
US10185803B2 (en) 2015-06-15 2019-01-22 Deep Genomics Incorporated Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network
EP3701534B1 (en) 2017-10-17 2024-04-10 Invitae Corporation Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis
US10978196B2 (en) * 2018-10-17 2021-04-13 Tempus Labs, Inc. Data-based mental disorder research and treatment systems and methods
US20200121715A1 (en) 2018-10-20 2020-04-23 MC Technology Holdings, LLC Composition comprising aqueous medium with reduced size water clusters to improve bioavailability of the aqueous medium and methods for making and using the compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000500647A (ja) 1995-10-24 2000-01-25 クレイジェン コーポレーション 配列決定を行なわないでサンプル中のｄｎａ配列を同定、分類または定量する方法及び装置
US20160306923A1 (en) 2013-01-17 2016-10-20 Edico Genome, Inc. Bioinformatics systems, apparatuses, and methods executed on an integrated circuit processing platform
WO2016154584A1 (en) 2015-03-26 2016-09-29 Quest Diagnostics Investments Incorporated Alignment and variant sequencing analysis pipeline
US20170270212A1 (en) 2016-03-21 2017-09-21 Human Longevity, Inc. Genomic, metabolomic, and microbiomic search engine

Also Published As

Publication number Publication date
US20230117854A1 (en) 2023-04-20
MX2020003709A (es) 2020-07-22
CN112074909A (zh) 2020-12-11
US20200251179A1 (en) 2020-08-06
US20190189246A1 (en) 2019-06-20
US11798651B2 (en) 2023-10-24
AU2018350975A1 (en) 2020-05-07
US11462299B2 (en) 2022-10-04
EP3701534A4 (en) 2021-08-04
JP2020537795A (ja) 2020-12-24
BR112020007449A2 (pt) 2020-10-20
US12136472B2 (en) 2024-11-05
CA3079389A1 (en) 2019-04-25
US20240006021A1 (en) 2024-01-04
IL274001A (en) 2020-05-31
AU2018350975B2 (en) 2023-11-23
EP3701534C0 (en) 2024-04-10
EP3701534B1 (en) 2024-04-10
CN112074909B (zh) 2024-03-19
EP3701534A1 (en) 2020-09-02
WO2019079464A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
JP7258871B2 (ja) 遺伝子及びゲノムの検査並びに分析におけるバリアント解釈の、監査可能な継続的な最適化のための分子エビデンスプラットフォーム
JP7390711B2 (ja) 個体およびコホートの薬理学的表現型予測プラットフォーム
Mitchell et al. National biobanks: clinical labor, risk production, and the creation of biovalue
US20200027557A1 (en) Multimodal modeling systems and methods for predicting and managing dementia risk for individuals
US20120310539A1 (en) Predicting gene variant pathogenicity
Ko et al. GWAS of longitudinal trajectories at biobank scale
Wyatt et al. Genders of patients and clinicians and their effect on shared decision making: a participant-level meta-analysis
Kobayashi et al. Clinical variant reclassification in hereditary disease genetic testing
Zhou et al. A phenome-wide scan reveals convergence of common and rare variant associations
Williams et al. 90-Day all-cause mortality can be predicted following a total knee replacement: an international, network study to develop and validate a prediction model
Hayakawa et al. Benzodiazepine-related dementia risks and protopathic biases revealed by multiple-kernel learning with electronic medical records
Tong et al. Explainable AI reveals tissue pathology and psychosocial drivers of opioid prescription for non-specific chronic low back pain
Sturla et al. Application of microarrays to neurological disease
Hu et al. PAD-associated genetic variants are more strongly associated with surgical intervention than premature onset
Guare et al. Enhancing genetic association power in endometriosis through unsupervised clustering of clinical subtypes identified from electronic health records
Chantou Genomic Analysis to Determine Genetic Risk Factors in Degenerative Diseases in the Elderly: Challenges and Opportunities in the Genomic Era
Gharahkhani et al. Genome-wide risk prediction of primary open-angle glaucoma across multiple ancestries
Kreft et al. Genetic subtypes predict multiple sclerosis severity and response to treatment
Ryan et al. 90‑Day all‑cause mortality can be predicted following a total knee replacement: an international, network study to develop and validate a prediction model
EP4634927A1 (en) Systems and methods for patient-specific treatment recommendation optimized with multistage machine learning
Sarata Genetic testing: Scientific background for policymakers
Jr et al. Genome-wide association study of treatment resistant depression highlights shared biology with metabolic traits
Ruderfer Genome-ide association stud of treatment-resistant depression: shared biolog ith metabolic traits
Dattani downloaded from the King’s Research Portal at https://kclpure. kcl. ac. uk/portal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221207

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230405

R150 Certificate of patent or registration of utility model

Ref document number: 7258871

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150